Gastroenterology News and Research RSS Feed - Gastroenterology News and Research

Gastroenterology is the branch of medicine where the digestive system and its disorders are studied.
NICE recommends REMICADE, HUMIRA and SIMPONI therapies for patients with ulcerative colitis

NICE recommends REMICADE, HUMIRA and SIMPONI therapies for patients with ulcerative colitis

The National Institute for Health and Care Excellence (NICE) has issued its Final Appraisal Document (FAD) recommending REMICADE (infliximab), HUMIRA (adalimumab) and SIMPONI (golimumab), within their marketing authorisations, as options for treating moderately to severely active ulcerative colitis (UC) in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies. [More]
Olympus receives FDA clearance for Narrow Band Imaging

Olympus receives FDA clearance for Narrow Band Imaging

Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, among other core businesses, announced today FDA 510(k) clearance of Narrow Band Imaging (NBI) as enabling effective targeting of biopsies not seen under white light and improved visualization of tumor boundaries in Non-Muscle-Invasive Bladder Cancer (NMIBC) patients. [More]
Abbott acquires control of Veropharm for $305 million

Abbott acquires control of Veropharm for $305 million

Abbott today announced that it has acquired control of Veropharm, a leading Russian pharmaceutical manufacturer. [More]
Research highlights potential of computers to enhance quality of care, medical outcomes

Research highlights potential of computers to enhance quality of care, medical outcomes

A computer system was more effective than doctors at collecting information about patient symptoms, producing reports that were more complete, organized and useful than narratives generated by physicians during office visits, according to a Cedars-Sinai study. [More]
FDA Advisory Committee votes in favor of Actavis' ceftazidime-avibactam

FDA Advisory Committee votes in favor of Actavis' ceftazidime-avibactam

Actavis plc today announced that the Anti-Infective Drugs Advisory Committee convened by the U.S. Food and Drug Administration has voted to recommend approval of Actavis' New Drug Application (NDA) for ceftazidime-avibactam, an investigational antibiotic being developed to treat hospitalized patients when limited or no treatment options are available for complicated intra-abdominal infections (cIAI) (in combination with metronidazole) and complicated urinary tract infections (cUTI) (including acute pyelonephritis) caused by Gram-negative pathogens. [More]
Ashish Nimgaonkar wins AGA-Boston Scientific Career Development Technology & Innovation Award

Ashish Nimgaonkar wins AGA-Boston Scientific Career Development Technology & Innovation Award

The American Gastroenterological Association Research Foundation is pleased to announce that Ashish Nimgaonkar, MBBS, MTech, MS, from John Hopkins University, has received the inaugural AGA-Boston Scientific Career Development Technology & Innovation Award. This award is graciously supported by a grant from Boston Scientific, a leading innovator of medical solutions. [More]
Study compares rates of clinically recorded fertility problems in women with and without celiac disease

Study compares rates of clinically recorded fertility problems in women with and without celiac disease

Women with celiac disease present with fertility problems no more often than women in the general population, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association. [More]
TxCell enrolls first patient in Ovasave phase IIb trial for treatment of refractory Crohn’s disease

TxCell enrolls first patient in Ovasave phase IIb trial for treatment of refractory Crohn’s disease

TxCell SA, a biotechnology company developing novel and innovative, cost-effective personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that it has enrolled the first patient in its phase IIb clinical trial of its lead product Ovasave in refractory Crohn’s disease. [More]
UC San Diego Health System, IVFCMG partner to enhance health care services

UC San Diego Health System, IVFCMG partner to enhance health care services

UC San Diego Health System and Imperial Valley Family Care Medical Group are pleased to announce a comprehensive affiliation that will enhance the depth and quality of multi-specialty health care services and clinical trials available to patients in the Imperial Valley and surrounding communities. [More]
Good Samaritan Hospital receives $417,560 grant to implement telemedicine program

Good Samaritan Hospital receives $417,560 grant to implement telemedicine program

The U.S. Department of Agriculture (USDA) Rural Development awards Good Samaritan Hospital, a prominent downtown Los Angeles hospital, a $417,560 grant to implement a telemedicine program that will connect members of the medical staff at Good Samaritan Hospital with public health and primary care providers and their patients at six Public Health sites on the island of Guam. [More]
BWH researchers identify two-faced role of TIM-3 protein

BWH researchers identify two-faced role of TIM-3 protein

A Brigham and Women's Hospital-led team has identified a long sought-after partner for a key immune protein, called TIM-3, that helps explain its two-faced role in the immune system -- sometimes dampening it, other times stimulating it. This newly identified partner not only sheds light on the inner workings of the immune system in diseases such as HIV, autoimmunity, and cancer, but also provides a critical path toward the development of novel treatments that target TIM-3. [More]
electroCore CEO highlights the importance of working with stakeholders when launching new technologies

electroCore CEO highlights the importance of working with stakeholders when launching new technologies

JP Errico, founder and CEO of electroCore, speaking at The FT Global Pharmaceutical and Biotechnology Conference in London last week, emphasized the importance of working with each of the major stakeholders, i.e., patients and their advocates, key opinion-leading physicians, and decision-makers within the payor community at the earliest opportunity, particularly in regards to innovative and disruptive technology such as electroCore’s non-invasive vagus nerve stimulation (nVNS). [More]
Oxford BioTherapeutics, Menarini Group initiate phase I study of OBT357 (MEN1112) for AML treatment

Oxford BioTherapeutics, Menarini Group initiate phase I study of OBT357 (MEN1112) for AML treatment

Oxford BioTherapeutics and Berlin Chemie/ Menarini Biotech/ Menarini Ricerche (belonging to Menarini Group) announce today that they have initiated the first-in-human clinical study of OBT357 (MEN1112), a novel enhanced antibody for the treatment of acute myeloid leukemia (AML). [More]
Researchers say that promoting healthy gut microbiota can help treat metabolic syndrome

Researchers say that promoting healthy gut microbiota can help treat metabolic syndrome

Promoting healthy gut microbiota, the bacteria that live in the intestine, can help treat or prevent metabolic syndrome, a combination of risk factors that increases a person's risk for heart disease, diabetes and stroke, according to researchers at Georgia State University and Cornell University. [More]
AGA's journals highlight important updates into treatments for cirrhosis, NAFLD

AGA's journals highlight important updates into treatments for cirrhosis, NAFLD

Cirrhosis and nonalcoholic fatty liver disease (NAFLD) are two serious liver conditions with limited pharmacological treatments. The December issues of AGA's journals -- Clinical Gastroenterology and Hepatology and Gastroenterology -- highlight important updates into treatments for these two debilitating diseases. [More]
Avantis Medical Systems' Third Eye Panoramic device for colonoscopy receives FDA clearance

Avantis Medical Systems' Third Eye Panoramic device for colonoscopy receives FDA clearance

Avantis Medical Systems, Inc., a technology leader in developing novel digital imaging devices, today announced that its Third Eye Panoramic device for colonoscopy has received 510(k) clearance from the U.S. Food & Drug Administration (FDA). [More]
High-absorption BCM-95 Curcumin can reduce spread of cancer cells

High-absorption BCM-95 Curcumin can reduce spread of cancer cells

A recently published cellular study on colorectal cancer showed that high-absorption BCM-95 Curcumin is able to reduce the spread of cancer cells and potentially increase the effectiveness of chemotherapy in the treatment of advanced colon cancer. [More]
Researchers explain interaction between HNRNPA2B1 protein and pancreatic cancer development

Researchers explain interaction between HNRNPA2B1 protein and pancreatic cancer development

Researchers from the University of Barcelona have described an interaction between the protein HNRNPA2B1 and pancreatic cancer development which remained unknown. The study, published in the journal Gastroenterology, has proved in human cancer cell lines that this protein is essential to the correct activity of the oncogenic protein KRAS, related to cancer start and development. [More]
SQI Diagnostics gets FDA clearance to market Celiac Panel in the US

SQI Diagnostics gets FDA clearance to market Celiac Panel in the US

SQI Diagnostics Inc. today announced that it has received notice that the United States Food and Drug Administration has cleared the Company to market its proprietary Celiac Panel in the United States (US). [More]
New AGA guidelines provide guidance on IBS treatments

New AGA guidelines provide guidance on IBS treatments

Up to 15 percent of the general adult population is affected by irritable bowel syndrome (IBS), and most patients struggle to find effective drug therapy. A new guideline from the American Gastroenterological Association provides these patients and their physician's guidance. [More]